Amylyx Pharmaceuticals Inc. has nominated AMX-0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia and other rare diseases.

2025 was a tumultuous year for the global healthcare sector. For much of the year, policy uncertainty, particularly around U.S. drug pricing and trade barriers,

THE WORLD IS FLAT FAT: More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds.

One in five local areas in England still do not provide the weight loss jab tirzepatide (Mounjaro) on the NHS six months after the drug

Your AI doctor’s office is expanding. On Jan. 7, OpenAI announced that over the coming weeks, it will roll out ChatGPT Health, a dedicated tab

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company’s dual agonist of the GLP-1 and

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions.

(MedPage Today) — Bariatric surgery and GLP-1 receptor agonists both reduced fat mass over 2 years of treatment, but surgery was associated with a more

Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body already produces called glucagon-like peptide-1 (GLP-1),

Glucagon-like peptide-1 (GLP-1) receptor agonists were associated with a lower vertebral fracture risk in patients with type 2 diabetes, according to a study published in

The Simply Good Foods Company (NASDAQ:SMPL) Q1 2026 Earnings Call Transcript January 8, 2026 The Simply Good Foods Company beats earnings expectations. Reported EPS is

REDMOND, Wash., Jan. 9, 2026 /PRNewswire/ — Prescryptive and Ilant Health today announced a collaboration to help employers access transparent GLP-1 pricing alongside expert, outcomes-driven

Big moves are continuing in the weight loss landscape in the new year following breakthrough research of GLP-1 medications and other methods. Weight-loss experts spoke

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal

Pharmaceutics, Vol. 18, Pages 86: The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis Pharmaceutics doi: 10.3390/pharmaceutics18010086

Drugs known as glucagon-like peptide-1 receptor agonists, colloquially called GLP-1 medications, have gone from relatively obscure diabetes treatments to blockbuster weight-loss medications. But is the

The new food pyramid has been flipped on its head, with HHS officials releasing guidance that prioritizes meat, dairy and vegetables and pushes whole grains

Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.

Abstract Aims The aim of this systematic review and meta-analysis was to evaluate the effect of GLP-1RAs on functional walking distance and the risk of

With weight loss drugs taking the world by storm, more people are exploring adding these seemingly medical marvels to their toolkits. But what is a

SACRAMENTO, Calif. — Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year.

JCM, Vol. 15, Pages 541: Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss Journal of Clinical Medicine doi: 10.3390/jcm15020541 Authors: Gunjan

Eli Lilly Company Overview Zacks Rank #1 (Strong Buy) Eli Lilly and Company (LLY) is one of the world’s largest and most diversified pharmaceutical companies.

The American aesthetics market is entering a more mature phase, marked by slower growth, greater category divergence and a shift toward operational efficiency rather than

President Donald Trump told The New York Times he has not used GLP-1 weight-loss drugs like Ozempic or Wegovy but joked he “probably should.” The

WHEN Abbie Taylor began using fat jabs she was transfixed by the results. Like millions on the GLP-1 drugs, the 26-year-old marvelled at her rapid

Early signs show popular weight loss drugs may curb more than just food cravings. GLP-1’s like Ozempic, Mounjaro may also help patients with addiction. —

Ask executives in the healthcare industry about the future market for weight-loss drugs and the analogies are telling: monthly GLP-1 medicine subscriptions like a streaming video

The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular

Obesity is a complex, multifactorial condition defined by excessive adiposity and associated health risks.1 The rising prevalence of obesity contributes to the increasing global burden

Popular weight loss drugs like GLP-1 injections are helping millions of people lose pounds. But a new study shows that stopping these medications can cause

It’s not a cure.

Data from Circana and Technomic reveal shifting dining habits among weight loss drug users

A new study finds that people who quit weight-loss medications, including GLP-1 drugs, regain weight four times faster than people who stop dieting or exercising

Mike Stobe/Getty Images President Donald Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs

The Daily Beast reports: Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs such